NEW HAVEN, Conn.--(BUSINESS WIRE)--Ikonisys Inc., a developer of cell-based diagnostic products for women’s health and oncology, announced today that it secured $30 million in Series E financing. New investor Goldman, Sachs & Co. joined existing investors Trevi Health Ventures, Palisade Capital, Everfin, Lakeview Capital Management, New Science Ventures, Promark Holdings SA, Saint Simeon - e Investimentos, Lda, and WHI Group. The financing follows FDA marketing clearance and successful market launch of two new diagnostic applications developed by the Company for use in conjunction with its proprietary Ikoniscope® digital microscopy platform. The utility of the Ikoniscope has been validated through its successful adoption by the major U.S. clinical laboratory companies.
